Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CONDOR: Durvalumab and Tremelimumab in R/M SCCHN
NCT02319044Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Apr 2015
- Primary completion
- Sep 2016
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 15
01
Overview
Phase 2, randomised, open-label trial in squamous cell carcinoma of the head and neck (HNSCC) comparing MEDI4736 Monotherapy, Tremelimumab Monotherapy and MEDI4736 + Tremelimumab (3 arms). Primary endpoint: Objective Response Rate at 6 months. Started Apr 2015; status: completed.
02
Drugs
durvalumabtremelimumab
03
Conditions
squamous cell carcinoma of the head and neck (HNSCC)
Beyond the preview
Go deeper on NCT02319044.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02319044.